Industry Insights

• 
  A Brief Overview of Emerging Target: STEAP Xiaobin
  July 11, 2025
  As the "low-hanging fruit" in drug discovery becomes increasingly scarce, pharmaceutical companies are shifting their focus toward novel targets. At this year's AACR Annual Meeting, AstraZeneca unveiled preclinical data for AZD0516, a drug candidate targe
• 
  2025 Q1: Oncology Business Competition Among MNCs Xiaobin
  June 04, 2025
  How did MNCs fare in the oncology field during Q1 of this year?
• 
  Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
  April 28, 2025
  This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.

• 
  Drug-Device Combination Products: Making a Step Towards Better Adherence Suzanne Elvidge
  August 01, 2025
  More than half of the world’s population takes at least one medication daily, but the safety and efficacy data from clinical trials isn’t always fully reflected in real world use.

• 
  Alzheimer’s Disease: Charting the Course from Plaques to Promise Muhammad Farhan Khalid
  May 28, 2025
• 
  Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines PR Newswire
  July 31, 2025
• 
  Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company PR Newswire
  July 31, 2025
  Dx&Vx (DXVX) has signed its first-ever global out-licensing agreement since its establishment.

• 
  Popular Products and Companies at PharmaSources.com (July 2025) PSI
  July 24, 2025
  Popular Products and Companies at PharmaSources.com
• 
  The Bitter Medicine is Good for Health: Research Progress on the Components and Pharmacological Activities of Coptis Chinensis Xiaomichong
  July 02, 2025
• 
  Popular Products and Companies at PharmaSources.com (January 2025) PSI
  January 15, 2025

• 
  Apeloa Pharmaceutical releases first ESG PharmaSources
  May 12, 2025
  Apeloa Pharmaceutical has released its first sustainability report. Apeloa’s 2024 Environmental, Social and Governance (ESG) report marks the start of continuous and responsible disclosure into the future.